DBV Technologies S.A. (DBVT) shares rallied 6.8% in the last trading session to close at $17. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 61.3% gain over the past four weeks.
The price surge can be attributed to growing investor optimism related to the company’s efforts in evaluating the use of Viaskin, its proprietary technology platform, to address food allergies, caused by a hypersensitive immune reaction. DBV Technologies’ food allergy programs include ongoing studies of Viaskin Peanut in peanut allergic toddlers aged between one and three years and children aged four through seven years.
This company is expected to post quarterly loss of $1.45 per share in its upcoming report, which represents a year-over-year change of -81.3%. Revenues are expected to be $1.48 million, up 38.3% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For DBV Technologies, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on DBVT going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
DBV Technologies is a member of the Zacks Medical - Biomedical and Genetics industry. One other stock in the same industry, Ultragenyx (RARE), finished the last trading session 1.6% higher at $33.97. RARE has returned 16.4% over the past month.
Ultragenyx's consensus EPS estimate for the upcoming report has changed -0.4% over the past month to -$1.23. Compared to the company's year-ago EPS, this represents a change of +12.1%. Ultragenyx currently boasts a Zacks Rank of #3 (Hold).
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in the coming year. While not all picks can be winners, previous recommendations have soared +112%, +171%, +209% and +232%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>DBV Technologies S.A. (DBVT) : Free Stock Analysis Report
Ultragenyx Pharmaceutical Inc. (RARE) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
